Sugi Predict

Sugi Predict / Compounds / SCHEMBL670686

SCHEMBL670686

SCHEMBL670686

CCOC(=O)c1ccc(OC)c(Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B2 P37059 1/20 0.65
▸ ALDH1A1 P00352 3/20 0.65
▸ HPGD P15428 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ MAPT P10636 3/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ CA12 O43570 2/20 0.54
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ CA7 P43166 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ CA14 Q9ULX7 2/20 0.54
▸ TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27700458 0.88 KDM4E (0.67) HSD17B2ALDH1A1HPGDCYP1A2CYP2D6
SCHEMBL2645488 0.85 HSD17B2 (0.51) HSD17B2ALDH1A1HPGDCYP1A2MAPT
SCHEMBL30506315 0.85 HSD17B2 (0.76) HSD17B2ALDH1A1CYP1A2CYP2C19MAPT
SCHEMBL1660365 0.85 HSD17B2 (0.76) HSD17B2ALDH1A1CYP1A2CYP2C19MAPT
SCHEMBL5866557 0.83 HSD17B2 (0.69) HSD17B2ALDH1A1HPGDCYP1A2MAPT
SCHEMBL16605593 0.83 MAPT (0.55) HSD17B2ALDH1A1HPGDCYP1A2MAPT
SCHEMBL36283 0.83 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2CYP2D6CYP2C19
SCHEMBL29810107 0.83 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2CYP2D6CYP2C19
SCHEMBL22468902 0.83 CA12 (0.61) HSD17B2ALDH1A1HPGDCYP1A2MAPT
SCHEMBL1353930 0.83 HSD17B2 (0.63) HSD17B2ALDH1A1HPGDCYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4558489-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-05-28 — — EP disclosed
CN-119585248-A Heteroaryl derivatives as DDR inhibitors 奇斯药制品公司 2025-03-07 — — CN disclosed
CN-119306597-A Preparation method of aromatic bromo-compound 阜阳欣奕华制药科技有限公司 2025-01-14 — — CN disclosed
WO-2024017876-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — WO disclosed
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 — — US disclosed
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 — — US disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 — — EP disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 — — EP disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 — — US disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 — — US disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 — — WO disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 — — US disclosed
US-20060293344-A1 Therapeutic Compounds BOYD F L 2006-12-28 — — US disclosed
US-7153855-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-12-26 — — US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 — — US disclosed
US-20050049260-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2005-03-03 — — US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 — — EP disclosed
EP-1366048-B1 PYRAZOLOPYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2004-08-25 — — EP disclosed
EP-1366048-A2 PYRAZOLOPYRIDINE DERIVATIVES SmithKline Beecham Corporation (US) 2003-12-03 — — EP disclosed
WO-2002072581-A2 PYRAZOLOPYRIADINE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293344-A1 Therapeutic Compounds PCSK9, ABCB1, ABCB11 HSD17B2 420/4885ALDH1A1 232/4885HPGD 475/4885
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 HSD17B2 4005/4885ALDH1A1 4786/4885HPGD 3539/4885
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 HSD17B2 832/4885ALDH1A1 1389/4885HPGD 299/4885
US-20050049260-A1 Therapeutic compounds ABCB1, PCSK9, ABCB11 HSD17B2 397/4885ALDH1A1 224/4885HPGD 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.